Next Day Disclosure Return
Filed with HKEX · Stock code 9966 · · 5 pages · English
Earlier from Alphamab Oncology
- 2026 Interim report
- 2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
- 2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
- Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
- Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
Later from Alphamab Oncology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.
- Voluntary announcement - latest research results of two phase iii clinical studies of anbenitamab (KN026) were presented at the 2026 esmo congress as lba oral presentations
- Voluntary announcement - results of a phase i/ii clinical study of JSKN033 in patients with cc following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
- Voluntary announcement - latest research updates of JSKN003 presented at the 2026 esmo congress
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology